19-20 February, 2019 | San Diego

 

Angle

Expertise Partner

ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.

www.angleplc.com

 

Guardant Health

Expertise Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.

www.guardanthealth.com

 

Sysmex Inostics

Program Partner

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a leader in blood-based molecular diagnostics testing in oncology.  Our highly sensitive OncoBEAM™ kits and tests offer a minimally-invasive alternative for the detection of cancer gene mutations, clinical trials testing and companion diagnostics development.

www.sysmex-inostics.com

For further information please don’t hesitate to send us an email.